Global Sickle Cell Disease Market, By Type (Sickle Cell Anemia, Sickle Hemoglobin- C Disease, Sickle Beta-Plus Thalassemia, Sickle Hemoglobin-D Disease, Sickle Hemoglobin-O Disease, Others), Diagnosis (Screening Tests, New-born Screening, Prenatal Screening, Others), Complications Type (Stroke, Acute Chest Syndrome, Pulmonary Hypertension, Organ Damage, Others), Treatment Type (Medication, Blood Transfusion, Bone Marrow Transplantation, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Sickle cell disease (SCD) is a red blood cell (RBC) problem caused by a genetic mutation that impairs haemoglobin, a protein that transports oxygen throughout the body. Acute chest syndrome, anemia, and vaso-occlusive crises (VOC) are only a few of the problems. SCD is currently treated by a blood and bone marrow transplant, which clinicians usually recommend. It entails removing the diseased bone marrow and replacing it with healthy bone marrow from a donor. Other successful therapies, including medicines and blood transfusions, are also being used because they canmedicines and blood transfusions. They are also being used to help patients lessen specific symptoms and live longer.
Data Bridge Market Research analyses that the sickle cell disease market was valued at USD 2,177.16 million in 2021 and is expected to reach USD 5,874.47 million by 2029, registering a CAGR of 13.21% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Type (Sickle Cell Anemia, Sickle Hemoglobin- C Disease, Sickle Beta-Plus Thalassemia, Sickle Hemoglobin-D Disease, Sickle Hemoglobin-O Disease, Others), Diagnosis (Screening Tests, New-born Screening, Prenatal Screening, Others), Complications Type (Stroke, Acute Chest Syndrome, Pulmonary Hypertension, Organ Damage, Others), Treatment Type (Medication, Blood Transfusion, Bone Marrow Transplantation, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy's Laboratories Ltd. (India), Gilead Sciences, Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Lupin (India), Allergan (Ireland)
Sickle cell disease (SCD) is a type of blood condition that is passed down from generation to generation. Haemoglobin with a defect is a symptom. This is the oxygen-carrying protein in red blood cells. As a result, sickle cell disease obstructs oxygen supply to tissues. Symptomatic relief and palliative care are currently accessible for sickle cell disease. Although bone marrow transplantation is the only cure for SCD, it is usually reserved for individuals under the age of 16 since bone marrow transplant risk in adults is too great. Blood transfusions, painkillers, and bone marrow transplants are all common treatments. The only two medications licensed for SCD are hydroxyurea and Endari. The potential launch of promising pipeline candidates such as crizanlizumab (SEG 101), voxelotor (GBT 440), Altemia and rivipansel is expected to boost the pharmacotherapy market's rapid expansion.
Sickle Cell Disease Market Dynamics
- Increasing prevalence of sickle cell disease
The rising prevalence of sickle cell disease across the globe is estimated to enhance the market's growth. Sickle cell anemia can have genotypic and phenotypic variances based on distinct mutations in hemoglobin genes. Approximately 300,000 new-borns are born with sickle cell disease every year, and 20 to 25 million people worldwide have inherited sickle cell features. People of African, Middle Eastern, and South Asian heritage are more likely to have sickle cell disease. The global market is likely to be driven by reasons such as increased immigration, improved healthcare services, and a large population of African heritage.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of sickle cell disease market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the sickle cell disease market. Additionally, rising level of disposable income and surging incidences of cases of blood related disorders are the major factors anticipated to flourish the market's growth rate during the forecast period of 2022-2029.
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the sickle cell disease market growth. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives. Researchers at the National Heart, Lung, and Blood Institute (NHLBI) in the United States, for instance, are developing genetic therapies to restore a lost gene or add a new DNA strain to improve cell function.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the sickle cell disease market growth during the forecast period.
On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the sickle cell disease market. Additionally, unavailability of drugs in rural areas and the lack of reimbursement will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This sickle cell disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the sickle cell disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Sickle cell disease is a series of inherited red blood cell abnormalities that damage oxygen-carrying protein's hemoglobin. More than 100,000 people in the United States and 20 million people globally are affected by the disease.
Sickle cell disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Sickle Cell Disease Market
The COVID-19 pandemic has far-reaching implications for the healthcare industry. The load on healthcare facilities and professionals was growing in tandem with the rapid increase in patient numbers. Many hospitals have decided to cancel or postpone procedures. The pandemic had a mixed influence on the sickle cell treatment market. The epidemic has put a strain on blood supplies, both in terms of demand and donor pool. As a result of the lockdown and travel restrictions, the number of donors has decreased and countless drives have been cancelled around the world. Furthermore, according to the pandemic in March 2020, more than 50,000 blood drives were postponed or rescheduled due to the American Red Cross Blood Services. As a result, there was a drop in the demand for blood transfusions and bone marrow transplants. Despite supply disruptions and new regulatory approvals, pharmaceutical companies reported positive growth in 2020.
- In December 2021, the U.S. Food and Drug Administration (FDA) announced the approval of drug named Oxbryta (voxelotor) for treating sickle cell disease in patients aged 4 up to 11 years. Oxbryta restores the proper form of a patient's red blood cells, decreasing damage to the body's tissues and red cells. In a phase 2 trial, 45 sickle cell disease patients aged four to eleven years were investigated for the efficacy and safety of Oxbryta.
Global Sickle Cell Disease Market Scope
The sickle cell disease market is segmented on the basis of type, diagnosis, complications type, treatment type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Sickle Cell Anemia
- Sickle Hemoglobin- C Disease
- Sickle Beta-Plus Thalassemia
- Sickle Hemoglobin-D Disease
- Sickle Hemoglobin-O Disease
- Acute Chest Syndrome
- Pulmonary Hypertension
- Organ Damage
- Screening Tests
- New-born Screening
- Prenatal Screening
- Blood Transfusion
- Bone Marrow Transplantation
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Sickle Cell Disease Market Regional Analysis/Insights
The sickle cell disease market is analyzed and market size insights and trends are provided by country, type, diagnosis, complications type, treatment type, route of administration, end-users and distribution channel as referenced above.
The countries covered in the sickle cell disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the sickle cell disease market because of the increased incidence rate of blood born disorders and surging level of investment in treatment of sickle cell disease in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to increasing number of patient population and surging level of disposable income in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel themarket's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Sickle Cell Disease Market Share Analysis
The sickle cell disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to sickle cell disease market.
Some of the major players operating in the sickle cell disease market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Dr. Reddy's Laboratories Ltd. (India)
- Gilead Sciences, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- AbbVie Inc. (U.S.)
- Lupin (India)
- Allergan (Ireland)